Ultrasensitive and Reversible Nanoplatform of Urinary Exosomes for Prostate Cancer Diagnosis

• Published in: ACS sensors Vol. 4; no. 5; pp. 1433 - 1441
• Main Authors: Li, Ping, Yu, Xiyuan, Han, Wujuan, Kong, Ying, Bao, Weiyang, Zhang, Jiaqi, Zhang, Wancun, Gu, Yueqing
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 24.05.2019
• Subjects: Cell Line, Tumor; DNA, Single-Stranded - analysis; Exosomes - metabolism; Humans; Limit of Detection; Male; Nanotechnology - methods; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Prostatic Neoplasms - urine; Ultracentrifugation; Urinalysis - methods; urinary exosomes; prostate specific membrane antigen; cancer biomarker; aptamer; prostate cancer diagnosis
• ISSN: 2379-3694; 2379-3694
• DOI: 10.1021/acssensors.9b00621

Prostate cancer cell-derived exosomes in urine have been extensively studied recently and regarded as novel biomarkers for cancer diagnosis and prognosis, which presents wide prospects in clinical applications. Sensitive detection and specific capture methods are essential for exosomes analysis. Herein, a dual functional platform composed of superparamagnetic conjunctions and molecular beacons (SMC-MB) is reported. The SMC-MB platform is designed based on aptamer immunoaffinity with ultrasensitive detection efficiency and reversible isolation capacity, which, respectively, profit from nonenzymatic amplification methods and magnetic separation along with restriction cleavage. It is noteworthy that exosomes quantification was exactly amplified and transformed into single strand DNA detection. Correlated measurements evidence that the limit of detection of SMC-MB is as low as ∼100 particles/μL in urine, and a linear relationship meets between the logarithmic concentration of exosomes and fluorescence intensity of the molecular beacon. Furthermore, employing prostate specific membrane antigen (PSMA) aptamer, the platform adapted to detect and capture PMSA-positive exosomes from urine samples provides excellent diagnostic efficiency for prostate cancer (PCa). The expression of typical biomarkers of PCa, i.e., PSA and PCA3 mRNA, is significantly higher in PSMA-positive exosomes. Altogether, the platform and strategy described in this paper are promising in urinary exosomes analysis and prostate cancer detection.